2.14% -0.145

Organon Co (OGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Organon Co Stock (OGN) Company Profile

Healthcare (1111)

551-430-6000

30 HUDSON STREET, JERSEY CITY

Prossima data di guadagno

Ultimi documenti SEC

OGN's Discussions on Twitter

Compare OGN vs LLY, JNJ, ABBV, NVS, AZN

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OGN Organon Co	6.72	1.79B	6.28B	700.00M	537.00M	2.6922
LLY Lilly Eli Co	978.37	896.18B	65.18B	20.64B	5.96B	22.59
JNJ Johnson Johnson	238.68	591.15B	94.19B	26.80B	19.70B	11.05
ABBV Abbvie Inc	231.41	417.62B	61.16B	4.19B	17.82B	2.3614
NVS Novartis Ag Adr	160.55	315.13B	54.72B	14.02B	15.32B	7.1855
AZN Astrazeneca Plc	197.78	312.52B	58.80B	10.24B	8.98B	3.2788

Organon Co Stock (OGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-09	Iniziato	Barclays	Underweight
2025-10-27	Downgrade	Piper Sandler	Overweight → Underweight
2025-05-02	Downgrade	Evercore ISI	Outperform → In-line
2024-09-06	Downgrade	JP Morgan	Neutral → Underweight
2023-11-03	Downgrade	Goldman	Buy → Neutral
2023-09-21	Iniziato	Barclays	Overweight
2023-03-16	Iniziato	Raymond James	Outperform
2022-10-14	Downgrade	BofA Securities	Neutral → Underperform
2022-09-06	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-08-05	Downgrade	BofA Securities	Buy → Neutral
2022-04-27	Iniziato	Goldman	Buy
2022-04-06	Ripresa	Morgan Stanley	Equal-Weight
2021-10-07	Iniziato	Piper Sandler	Neutral
2021-09-01	Iniziato	BofA Securities	Buy
2021-07-22	Iniziato	Citigroup	Buy
2021-06-15	Iniziato	JP Morgan	Neutral
2021-06-11	Iniziato	Morgan Stanley	Equal-Weight
2021-06-10	Iniziato	Evercore ISI	Outperform

Mostra tutto

Organon Co Borsa (OGN) Ultime notizie

Organon Co Azioni (OGN) Dati Finanziari

Organon Co (OGN)

Organon Co Stock (OGN) Company Profile

Compare OGN vs LLY, JNJ, ABBV, NVS, AZN

Organon Co Stock (OGN) Upgrades & Downgrades

Organon Co Borsa (OGN) Ultime notizie

Organon & Co. Hits Day Low of $7.50 Amid Price Pressure - Markets Mojo

Organon (OGN) HR chief gets stock awards, withholds shares for taxes - Stock Titan

Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February - MarketBeat

Organon (OGN) CFO granted shares, withholds stock to pay taxes - Stock Titan

Organon (OGN) executive reports PSU share awards and tax withholding - Stock Titan

Organon (OGN) CIO logs stock awards and tax withholding share disposals - Stock Titan

Organon (OGN) GC Weaver gets stock awards, shares withheld for tax - Stock Titan

Organon (NYSE: OGN) interim CEO reports stock awards and tax share offsets - Stock Titan

Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity? - simplywall.st

Organon & Co. (OGN) Stock Analysis: Key Insights On Its 25.17% Potential Upside - DirectorsTalk Interviews

KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome - marketscreener.com

KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS - GlobeNewswire Inc.

Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages - MarketBeat

OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis - Bitget

Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

OGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Organon presents sleep improvement data for VTAMA cream in children By Investing.com - Investing.com Australia

Organon presents sleep improvement data for VTAMA cream in children - Investing.com

Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN - MarketBeat

Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit - Sahm

Organon & Co. Confronts Mounting Global Pricing Pressure as Health Reforms Threaten Margin Stability and Nexplanon Growth - TipRanks

Organon & Co. (NYSE:OGN) Trading Down 6.3%Time to Sell? - MarketBeat

Organon & Co. (OGN) Stock Analysis: Navigating a Potential Upside Amidst a Challenging Landscape - DirectorsTalk Interviews

Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus

Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Organon & Co. (NYSE:OGN) Price Target Raised to $8.00 at Barclays - MarketBeat

Organon price target raised to $8 from $7.50 at Barclays - TipRanks

Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals By Investing.com - Investing.com India

Organon & Co. (OGN) posts FY adjusted EPS of $3.66, EBITDA margin at 30.7% - MSN

Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% - Insider Monkey

Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus - TechStock²

Organon Signs Deal for Global Rights to Sebela's Miudella Intrauterine Device - marketscreener.com

Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals - Investing.com

Organon Licenses MIUDELLA® to Enhance Women's Health Commitment - Intellectia AI

Organon enters into agreement to license Miudella® - marketscreener.com

First hormone-free copper IUD in 40 years lands $27.5M Organon deal - Stock Titan

Organon (OGN) Is Up 9.6% After Weaker 2025 Earnings And New 2026 Revenue GuidanceWhat's Changed - simplywall.st

Organon rises after update on independent review - MSN

Organon climbs 6% after audit clears company of wrongdoing - MSN

Organon Shares Rally as Investigation Clears Company of Wrongdoing - AD HOC NEWS

Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty - Seeking Alpha

Organon & Co. (NYSE:OGN) Shares Up 6.6%What's Next? - MarketBeat

Sector Update: Health Care - marketscreener.com

Organon Says Audit Review of Biosimilar Purchases Finds No Issues - marketscreener.com

Organon & Co. audit committee completes review of biosimilar purchase timing By Investing.com - Investing.com South Africa

Organon & Co. audit committee completes review of biosimilar purchase timing - Investing.com Nigeria

Organon rises after update on independent review (OGN:NYSE) - Seeking Alpha

Organon Audit Review Finds No Issues, 10-K On Track - TipRanks

Organon shares jump 6% after audit finds no misconduct By Investing.com - Investing.com India

Organon shares jump 6% after audit finds no misconduct - Investing.com

Organon (OGN) audit review finds no misconduct, plans timely 2025 10-K - Stock Titan

Organon Co Azioni (OGN) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a OGN